Dr. Post's groundbreaking contributions to biomedical engineering have led to significant progress in the development of next-generation cardiovascular devices. Her leadership within the Houston innovation ecosystem underscores her dedication to fostering collaboration and driving forward medical innovation.
Dr. Hartzell Schaff is recognized for his transformative contributions to cardiovascular medicine, with over 1,200 peer-reviewed papers and nine textbooks to his name. The award celebrates his impact on surgical techniques and patient care worldwide.
Dr. Jorge A. Miranda joins The Texas Heart Institute as leader of the newly established Limb Preservation Clinic, enhancing cardiovascular care for patients at risk for limb-threatening conditions. The clinic offers a team-based approach addressing immediate and underlying causes of peripheral vascular disease and cardiovascular disease.
A multi-institutional team is creating innovative technologies to reduce complications associated with left ventricular assist devices (LVADs), including infection, thrombosis, stroke, and bleeding. The new LVAD will deliver a physiological response to changes in the recipient's activity levels using a 'smart' Maglev drive technology.
Researchers aim to address LVAD shortcomings, reducing blood damage and clotting risk through innovative designs and coatings. A novel flexible stented blood inlet and slippery hydrophilic coatings will be used to prevent flow stasis and clot formation.
A study published in Nature Cardiovascular Research reveals that a dynamic synergy between cell types facilitates cardiac renewal, challenging existing paradigms. Targeting the microenvironment rather than specific cell types is key to healing injured hearts.
A team of researchers from Texas Heart Institute and Baylor College of Medicine have made a significant discovery about the underlying molecular cell states within transplanted pediatric hearts. They found that donor-derived tissue-resident macrophages are crucial for graft acceptance, but their loss leads to allograft failure.
A new tool, developed with a machine learning-based approach, can predict diuretic response in patients with ADHF. The BAN-ADHF score may lead to personalized strategies for effectively managing congestion in hospitalized patients.
Researchers develop injectable hydrogel electrodes for treating ventricular arrhythmia, providing a potential solution to painful defibrillation and improving quality of life. The novel pacing modality addresses the pathophysiology of re-entrant arrhythmia and offers a promising alternative to existing therapies.
The Texas Heart Institute has received a five-year, $2 million grant from the National Institutes of Health to advance organ bioengineering. The project aims to develop transplantable bioartificial hearts to combat end-stage heart failure.
The Texas Heart Institute has been awarded $1.14 million by the NIH to develop a novel, first-in-class drug for treating atherosclerotic cardiovascular disease. The goal of this research is to target lingering inflammation in patients with cardiovascular disease.
The Texas Heart Institute and The University of Texas at Austin receive a four-year, $2.37 million NIH grant to develop injectable hydrogel electrodes for preventing and managing ventricular arrhythmias. Researchers have already demonstrated the feasibility of pacing the heart using the hydrogel in a porcine model.
A new cell therapy has demonstrated significant benefits in improving the heart's pumping ability and reducing the risk of cardiovascular death, heart attack, or stroke in patients with chronic heart failure. The therapy, using mesenchymal precursor cells (MPCs), also showed a strong signal in reducing inflammation and improving microv...
Researchers at the Texas Heart Institute have made significant breakthroughs in treating persistent heart failure with a novel stem cell therapy. The phase 3 clinical trial results show that this treatment has the potential to alter the natural history of heart disease, reducing hospitalizations and improving patient outcomes.
The study found that the Wntless (Wls) gene plays a critical role in heart regeneration in mice by facilitating signal molecule secretion from cardiomyocytes to cardiac fibroblasts. This promotes heart functional recovery by suppressing CF activation and reducing scar formation.
Researchers have identified the potential of 7HP349 as an oral medication to strengthen the effectiveness of vaccines, particularly for populations that struggle with immunosuppression. The study suggests adding 7HP349 to standard vaccination can improve vaccine efficacy without reformulating the vaccine.
The Texas Heart Institute has developed a breakthrough ex vivo benchtop system for evaluating the effects of ablation systems on excised tissues, shedding light on the need for esophageal temperature monitoring during HPSD ablation. The study highlights the importance of safety measures in clinical settings and paves the way for furthe...
The collaboration aims to develop a small molecule drug targeting inflammatory cell trafficking in the gut, offering a safe alternative to current treatments for IBD. The company will apply its proprietary approach to develop antagonists of integrin targets.
The Texas Heart Institute will develop the first fully implantable circulatory support device for pediatric patients, aiming to stop advanced heart failure progression. Led by Dr. O.H. Frazier, the team will conduct preclinical studies and collaborate with international consultants.
A new study aims to enhance cord blood transplant success rates using a small molecule cell adhesion activator. The treatment has shown promise in preclinical studies and may provide a safer alternative to current methods.
Researchers developed a wirelessly powered, leadless pacemaker that can synchronize both sides of the heart, reducing complications associated with traditional pacemakers. The device has shown impressive clinical outcomes measures and is being further miniaturized for implantable use.
Leslie Gonzalez, a Texas Heart Institute perfusion student, has been awarded the prestigious Perfusion Without Borders scholarship. She will travel with The Novick Cardiac Alliance to Medellin, Colombia in February 2020, gaining experience on global perfusion practices and preparing for lifelong involvement in mission work.
The Texas Heart Institute is developing a novel pacemaker system that is both leadless and wirelessly powered. The new pacemakers allow simultaneous pacing and sensing from multiple sites in the heart to help reduce complications associated with traditional pacemakers.